Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021

·1 min read

WOODCLIFF LAKE, N.J., October 28, 2021--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens.

Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date

Tuesday, November 9, 2021

Time

8:30 a.m. ET

Toll free (U.S.)

866-342-8591

International

203-518-9822

Webcast (live and replay)

www.eagleus.com, under the "Investor Relations" section

A replay of the conference call will be available for one week after the call's completion by dialing 800-839-8292 (US) or 402-220-6069 (International) and entering conference call ID EGRXQ321. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006236/en/

Contacts

Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting